Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
ERNAW
$0.03
+16.08%
ERNAW
· Ernexa Therapeutics Inc.
$0.03
+0.00 (+16.08%)
At close · Oct 28
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of June 30, 2026, the Company had approximately $5.0 million in cash, which is less than that needed to effect its current operating plan and forecasted cash requirements for the next twelve months. However, management expects that its ability to access capital under its ATM will cover shortfalls in its cash resources over the next twelve months from the issuance date of these financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$3.25M
Shares
1.63M
Volume · Oct 28
781
Avg daily vol (3M)
25.96K
All webcasts
Earnings call · FY2020 Q1
Ernexa Therapeutics Inc. (ERNAW) Q1 2020 Earnings Call
Revenue
$2.39M
-50.5% YoY
Diluted EPS
-$450.00
Net income
-$1.02M
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed May 19, 2020 · complete as-filed document
SEC periodic report
10-Q report
Filed May 20, 2020 · complete as-filed document